FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3038386903> ?p ?o ?g. }

• W3038386903 endingPage "108074" @default.
• W3038386903 startingPage "108074" @default.
• W3038386903 abstract "COVID-19 has devastated Americans across many communities, bringing unprecedented challenges to our economy, our healthcare system, and our way of life as we knew it. Like many historical moments and life-changing events, the COVID-19 pandemic has forced us to look inward and reflect deeply on our existing systems, shining a painful light on profound inequities and shortcomings of our healthcare and social support structures. The addiction treatment system is no exception. While there is growing recognition among experts that opioid use as a leading public health problem, addiction treatment programs remain siloed from the healthcare system and burdened with protocols based on punitive ideologies rather than evidence-based practices. Despite overwhelming evidence for methadone and buprenorphine, two opioid agonists that substantially reduce overdose risk (Sordo et al., 2017Sordo L. Barrio G. Bravo M.J. et al.Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies.BMJ. 2017; 357https://doi.org/10.1136/bmj.j1550Crossref PubMed Scopus (1019) Google Scholar), these medications remain highly controlled and inaccessible to most individuals in need of treatment for opioid use disorder. Strict regulations on the provision of such medications, often upheld as necessary to promote safety and avoid illicit diversion, are deeply embedded in a culture of stigma and criminalization that instead limit their use (Doernberg et al., 2019Doernberg M. Krawczyk N. Agus D. Fingerhood M.I. Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?.Substance Abuse. 2019; 40: 148-153Crossref PubMed Scopus (38) Google Scholar). This approach has generated treatment programs that prioritize adherence to rules, whether or not they are rational and effective, rather than promoting inclusion and retention. Like most patients failed by our current health system, those who suffer the most are the same vulnerable groups that will likely be hardest hit by COVID-19: Those who are victims of poverty, trauma, and discrimination and who frequently suffer from co-occurring conditions, such as depression, heart disease, HIV, and other illnesses. Yet this restrictive approach has dramatically changed overnight, not because the paradigm has suddenly changed, but because the COVID-19 health crisis emerged. In just a matter of weeks, swift modifications in our opioid treatment regulations that the Substance Abuse and Mental Health Administration announced in March 2020 have revealed an alternative reality by which patients with opioid use disorder in the U.S. can now access treatment. Longer take-homes for methadone—which previously were only allowed after a patient completed years of daily visits to clinics—are now considered standard. Buprenorphine treatment initiation—previously requiring a lengthy evaluation process by a waivered physician followed by frequent monitoring—can now be done over a simple phone call. Mandates for supervised urine drug screens and in-person behavioral counseling sessions have been largely relinquished or adapted to be remote. At the same time, the drive to prevent the spread of COVID-19 in detention centers has led to the unprecedented dismissal of thousands of low-level drug charges, which would have otherwise led to the incarceration of many drug users with minimal or no access to effective treatment. These changes are a reaction borne out of necessity to prevent a disastrous surge of COVID-19 cases and a simultaneous surge in relapse and overdose deaths (Becker and Fiellin, 2020Becker W.C. Fiellin D.A. When epidemics collide: Coronavirus Disease 2019 (COVID-19) and the opioid crisis.Annals of Internal Medicine. 2020; https://doi.org/10.7326/M20-1210Crossref Scopus (164) Google Scholar). Social distancing policies and quarantine orders made requirements for numerous in-person visits and high vigilance of patients unrealistic and unsustainable. The truth, however, is that these requirements were never realistic or sustainable. Years of research have shown that requiring frequent visits, heavy monitoring, and mandatory participation in adjunct services to be eligible for life-saving medications created unnecessary barriers to accessing care (Krawczyk et al., 2019Krawczyk N. Buresh M. Gordon M.S. Blue T. Fingerhood M.I. Agus D. Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap.Journal of Substance Abuse Treatment. 2019; 103: 1-8Abstract Full Text Full Text PDF PubMed Scopus (64) Google Scholar). Obstacles, such as long transportation times, difficulty managing appointments around work and childcare responsibilities, and the stigma associated with waiting in long lines to access treatment or provide urine drug tests under supervision, impede initiation and retention in treatment (Reisinger et al., 2009Reisinger H.S. Schwartz R.P. Mitchell S.G. et al.Premature discharge from methadone treatment: Patient perspectives.Journal of Psychoactive Drugs. 2009; 41: 285-296https://doi.org/10.1080/02791072.2009.10400539Crossref PubMed Scopus (79) Google Scholar). These barriers have not only resulted in limited utilization of available treatment programs but have likely helped to sustain an illicit market of buprenorphine that allows opioid users to access treatment and reduce overdose risk more easily than enrolling in a formal treatment program (Carlson et al., 2020Carlson R.G. Daniulaityte R. Silverstein S.M. Nahhas R.W. Martins S.S. Unintentional drug overdose: Is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose?.International Journal of Drug Policy. 2020; 79: 102722https://doi.org/10.1016/j.drugpo.2020.102722Crossref PubMed Scopus (52) Google Scholar). Similarly, the health risks associated with crowded jails and cycling in and out of the criminal justice system did not begin with COVID-19: For decades, incarceration has created devastating outcomes for public health (Wildeman and Wang, 2017Wildeman C. Wang E.A. Mass incarceration, public health, and widening inequality in the USA.Lancet. 2017; 389: 1464-1474https://doi.org/10.1016/S0140-6736(17)30259-3Abstract Full Text Full Text PDF PubMed Scopus (471) Google Scholar), increasing risk for overdose, trauma, homelessness, and reduced access to healthcare. The current morass and devastation of COVID-19, therefore, offers an opportunity to adopt a much-needed revision to the status-quo and create a more sustainable, equitable, and harm reduction–oriented system. Existing models for services both in the U.S. and other countries exemplify the potential for offering opioid treatment through more accessible mechanisms (Calcaterra et al., 2019Calcaterra S.L. Bach P. Chadi A. et al.Methadone matters: What the United States can learn from the global effort to treat opioid addiction.Journal of General Internal Medicine. 2019; 34: 1039-1042https://doi.org/10.1007/s11606-018-4801-3Crossref PubMed Scopus (63) Google Scholar; Krawczyk et al., 2019Krawczyk N. Buresh M. Gordon M.S. Blue T. Fingerhood M.I. Agus D. Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap.Journal of Substance Abuse Treatment. 2019; 103: 1-8Abstract Full Text Full Text PDF PubMed Scopus (64) Google Scholar), and simultaneously reducing both the over-regulation of scheduled agonist medications and the criminalization of drug use (Quintas and Arana, 2017Quintas J. Arana X. Decriminalization: Different models in Portugal and Spain.in: Dual Markets: Comparative Approaches to Regulation. Springer International Publishing, 2017: 121-143https://doi.org/10.1007/978-3-319-65361-7_8Crossref Scopus (7) Google Scholar). In addition, new protocols developed in response to COVID-19 will provide a natural experiment for clinicians, researchers, and advocates to study the impact of lower threshold treatment on patient health and overdose risk. These examples provide a path for the U.S. to follow when the COVID-19 crisis passes, and an opportunity to re-build an addiction treatment system focused on health rather than character reformation or punishment. In this way, this experience can contribute to much-needed improvements in addressing the overdose epidemic and a chance to reduce long-term inequities and suffering across our communities." @default.
• W3038386903 created "2020-07-10" @default.
• W3038386903 creator A5000139333 @default.
• W3038386903 creator A5074186779 @default.
• W3038386903 creator A5077801791 @default.
• W3038386903 date "2020-10-01" @default.
• W3038386903 modified "2023-10-11" @default.
• W3038386903 title "Lessons from COVID 19: Are we finally ready to make opioid treatment accessible?" @default.
• W3038386903 cites W2118400166 @default.
• W3038386903 cites W2604936718 @default.
• W3038386903 cites W2912757607 @default.
• W3038386903 cites W2941498941 @default.
• W3038386903 cites W2944589765 @default.
• W3038386903 cites W3014861007 @default.
• W3038386903 cites W3016822260 @default.
• W3038386903 doi "https://doi.org/10.1016/j.jsat.2020.108074" @default.
• W3038386903 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7336118" @default.
• W3038386903 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32680610" @default.
• W3038386903 hasPublicationYear "2020" @default.
• W3038386903 type Work @default.
• W3038386903 sameAs 3038386903 @default.
• W3038386903 citedByCount "22" @default.
• W3038386903 countsByYear W30383869032020 @default.
• W3038386903 countsByYear W30383869032021 @default.
• W3038386903 countsByYear W30383869032022 @default.
• W3038386903 countsByYear W30383869032023 @default.
• W3038386903 crossrefType "journal-article" @default.
• W3038386903 hasAuthorship W3038386903A5000139333 @default.
• W3038386903 hasAuthorship W3038386903A5074186779 @default.
• W3038386903 hasAuthorship W3038386903A5077801791 @default.
• W3038386903 hasBestOaLocation W30383869031 @default.
• W3038386903 hasConcept C116675565 @default.
• W3038386903 hasConcept C118552586 @default.
• W3038386903 hasConcept C126322002 @default.
• W3038386903 hasConcept C142724271 @default.
• W3038386903 hasConcept C15744967 @default.
• W3038386903 hasConcept C159047783 @default.
• W3038386903 hasConcept C170493617 @default.
• W3038386903 hasConcept C17744445 @default.
• W3038386903 hasConcept C199539241 @default.
• W3038386903 hasConcept C2777170798 @default.
• W3038386903 hasConcept C2778137277 @default.
• W3038386903 hasConcept C2779134260 @default.
• W3038386903 hasConcept C2779473830 @default.
• W3038386903 hasConcept C2781063702 @default.
• W3038386903 hasConcept C2909376813 @default.
• W3038386903 hasConcept C3006700255 @default.
• W3038386903 hasConcept C3007834351 @default.
• W3038386903 hasConcept C3008058167 @default.
• W3038386903 hasConcept C524204448 @default.
• W3038386903 hasConcept C71924100 @default.
• W3038386903 hasConcept C89623803 @default.
• W3038386903 hasConceptScore W3038386903C116675565 @default.
• W3038386903 hasConceptScore W3038386903C118552586 @default.
• W3038386903 hasConceptScore W3038386903C126322002 @default.
• W3038386903 hasConceptScore W3038386903C142724271 @default.
• W3038386903 hasConceptScore W3038386903C15744967 @default.
• W3038386903 hasConceptScore W3038386903C159047783 @default.
• W3038386903 hasConceptScore W3038386903C170493617 @default.
• W3038386903 hasConceptScore W3038386903C17744445 @default.
• W3038386903 hasConceptScore W3038386903C199539241 @default.
• W3038386903 hasConceptScore W3038386903C2777170798 @default.
• W3038386903 hasConceptScore W3038386903C2778137277 @default.
• W3038386903 hasConceptScore W3038386903C2779134260 @default.
• W3038386903 hasConceptScore W3038386903C2779473830 @default.
• W3038386903 hasConceptScore W3038386903C2781063702 @default.
• W3038386903 hasConceptScore W3038386903C2909376813 @default.
• W3038386903 hasConceptScore W3038386903C3006700255 @default.
• W3038386903 hasConceptScore W3038386903C3007834351 @default.
• W3038386903 hasConceptScore W3038386903C3008058167 @default.
• W3038386903 hasConceptScore W3038386903C524204448 @default.
• W3038386903 hasConceptScore W3038386903C71924100 @default.
• W3038386903 hasConceptScore W3038386903C89623803 @default.
• W3038386903 hasLocation W30383869031 @default.
• W3038386903 hasLocation W30383869032 @default.
• W3038386903 hasLocation W30383869033 @default.
• W3038386903 hasOpenAccess W3038386903 @default.
• W3038386903 hasPrimaryLocation W30383869031 @default.
• W3038386903 hasRelatedWork W2420168943 @default.
• W3038386903 hasRelatedWork W3003901880 @default.
• W3038386903 hasRelatedWork W3004826915 @default.
• W3038386903 hasRelatedWork W3005417802 @default.
• W3038386903 hasRelatedWork W3007868867 @default.
• W3038386903 hasRelatedWork W3016721635 @default.
• W3038386903 hasRelatedWork W3020699490 @default.
• W3038386903 hasRelatedWork W3031607536 @default.
• W3038386903 hasRelatedWork W3087206508 @default.
• W3038386903 hasRelatedWork W4206419631 @default.
• W3038386903 hasVolume "117" @default.
• W3038386903 isParatext "false" @default.
• W3038386903 isRetracted "false" @default.
• W3038386903 magId "3038386903" @default.
• W3038386903 workType "article" @default.